SK pharmteco’s subsidiary Yposkesi launches AAVelocity, a plug-and-play Adeno-Associated Virus (AAV) platform
Designed to shorten turnaround on manufacturing AAVs, this new platform offers Cell and Gene Therapy developers more flexibility in producing viral vectors for clinical and commercial use Evry-Courcouronnes (near Paris), France, November 7, 2023 – Yposkesi, SK pharmteco’s European clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapies (C>), today launches AAVelocityTM, […]
